Skip to main content
NUTRITION 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session: Polyphenols: Metabolism and Health (Oral 18)

(OR18-06-24) Oat-Derived Bioactives (Avenanthramide and Beta-glucan) Increase the Velocity of and Accelerate Wound Healing

Monday, July 1, 2024
9:00 AM – 9:12 AM CT
Location:  W183

    Presenting Author(s)

  • Vincent W. Li, MD, M.B.A.

    COO and Scientific Director
    The Angiogenesis Foundation
    Cambridge, Massachusetts, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • William W. Li, M.D.

    President and Medical Director
    Angiogenesis Foundation
    Cambridge, Massachusetts, United States

  • AM

    Abigail A. Miller, A.B.

    Angiogenesis Foundation

  • HK

    Hudson C. Kussie, B.A.

    University of Arizona College of Medicine
    Tucson, Arizona, United States

  • KC

    Kellen Chen, Ph.D.

    University of Arizona College of Medicine
    Tucson, Arizona, United States

  • GG

    Geoffrey C. Gurtner

    University of Arizona College of Medicine
    Tucson, Arizona, United States

Objectives: Oats (Avena sativa) are an important whole grain with lipid lowering and anti-inflammatory effects. Recent studies revealed that oat-derived bioactives, avenanthramide (AVE) and beta-glucan (βG), stimulate wound healing by inducing angiogenesis and recruiting endothelial progenitor cells. We here report the effect of AVE and βG on healing velocity and acceleration, characterizing wound healing dynamics.

Methods: AVE and βG extracted from whole oats were solubilized in buffer (0.1%, 0.5%, 1%) and applied by SQ injection to the margins of full-thickness excisional wounds on the dorsum of C57BL/6 mice every two days and compared to controls. Surface planimetry was assessed using digital photographs taken every two post-operative days. The velocity of wound healing (Δwound area/Δtime) induced by each bioactive was calculated by linear regression as the slope between time points; acceleration (Δvelocity/Δtime) was determined as a higher order curve.

Results: Compared to controls, both AVE and βG resulted in greater healing velocity, with distinct temporal dynamics. An early effect was observed with βG (before POD 2) while AVE had a later effect on healing velocity (after POD 2). 1% AVE resulted in the highest maximum velocity compared to control (21.7 vs.11.7), a 1.9-fold faster healing speed. Both 1% and 0.1% βG achieved comparable maximum velocities (21.4 vs and 21.3) but earlier in the healing process. Analysis of wound healing acceleration revealed differential dynamics between bioactives.

Conclusions: Oat bioactives augment normal wound healing by improving wound healing dynamics. This is the first description of wound healing velocity and acceleration induced by AVE and βG, correlated with faster wound closure in vivo. Velocity and acceleration are novel metrics that characterize the dynamic biological effect of oat bioactives beyond completed wound closure.

Funding Sources: AVE and βG supplied by Ceapro, Inc., Edmonton, Alberta.